Sector News

With no CEO, Sanofi faces battle to sell pipeline ambitions

November 13, 2014
Life sciences
(Reuters) – Sanofi has worked hard to refill its medicine chest with new drugs it will tout to investors next week, but these efforts are now clouded by a leadership vacuum and uncertainties about diabetes.
 
The timing is unfortunate. Two weeks ago, Sanofi’s board sacked its chief executive of six years, Chris Viehbacher, blaming his brusque management style.
 
His ousting, which followed a warning that sales growth at Sanofi’s top diabetes business would stall next year, stunned investors who had hailed Viehbacher’s efforts to make the firm more global.
 
The Nov. 20 investor day is the first test of the post-Viehbacher era and a challenge for Chairman Serge Weinberg, who has taken the helm while Sanofi hunts for a new boss. He has already said there will be no more guidance on financial prospects until annual results in February.
 
“Chris Viehbacher had a very clear strategy. And all that is kind of up in the air now,” said Andrea Williams, European fund manager at Royal London Asset Management, which sold part of its Sanofi holding as it waits to see who will be appointed CEO.
 
The new medicines seminar will be held at the U.S. headquarters of Sanofi’s Genzyme rare diseases unit and will focus on products set to launch next year, including the world’s first vaccine against dengue fever, its injectable cholesterol-lowering drug alirocumab and the allergy treatment dupilumab.
 
One crucial question Sanofi will face is how to rekindle its fortunes in diabetes, a market that has been its cash cow for years as obesity increases.
 
Sanofi said last month it faced tough times with its top-selling insulin Lantus in the United States – and its pricing power is set to shrink further as so-called biosimilar copies enter the market over the next two years.
 
Sanofi stockholders are thus likely to press for answers on the prospects of its longer-acting version of Lantus, dubbed Toujeo, and of an inhaled insulin called Afrezza.
 
“They have a lot going for them. It’s not a bad company,” said Geir Lode, head of Hermes Global Equities, which owns Sanofi stock. He says the group needs to clearly spell out its strategic intentions, from diabetes to mergers and acquisitions.
 
“It’s all about clarification. I feel like I’m walking in the fog now, I see nothing and I need the sun to come out.” 
 
By Natalie Huet (Editing by Ben Hirschler and Vincent Baby)

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend